John McCamant


Medical Technology Stock Letter

  • #1 Portfolio Performance of >500 by Hulbert’s Financial Digest in 2013
  • 2018 MoneyShow Top Pick MDGL up 575% ($15.96-91.79)
  • 2019 MoneyShow Top Pick MDCO up 457% ($18.57-84.90)

About John

John McCamant was named editor of the Medical Technology Stock Letter in August 2000. He has spent 35 years on the front lines of biotechnology investing as an equities analyst and in venture capital. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, BusinessWeek, Reuters, and Bloomberg.

John's Articles

In the first quarter of 2022, Incyte Pharmaeuticals (INCY) reported a very strong quarterly results, highlighted by the solid launch of Opzelura, observes John McCamant, biotech sector specialist and editor of The Medical Technology Stock Letter.
In our 30-year history, we have made several recommendations that comprised companies with revolutionary platform technologies, suggests John McCamant, biotech sector specialist and editor of The Medical technology Stock Letter.
Sangamo Therapeutics (SGMO) recently announced the dosing of the first patient in a landmark trial to prevent transplanted kidney rejections, explains John McCamant, editor of The Medical Technology Stock Letter — and a participant in The MoneyShow Las Vegas on May 9-11.
We believe that the near-term selling is behind for the SPDR S&P Biotech ETF (XBI) on a technical basis as well as fundamentally, suggests John McCamant, biotech sector specialist and editor of The Medical Technology Stock Letter.

John's Videos

Among the recently completed Q1 earnings reports, there were a handful of successful biotechs with improving sales/earnings and higher forecasts from new product launches. In biotech, Bear market investors demand positive growth trends from new, approved drugs and avoid regulatory or clinical risk.

Tax loss selling in December offers oversold biotechs that will bounce nicely into the new year, creating what is known as the "January Effect."
Covid-19 vaccines have shown the world that biotech is truly a transformative industry. Join Bioinvest's John McCamant to learn how he picks game-changing biotech stocks to super charge your portfolio.
Biotech Covid-19 vaccine development has demonstrated the power of biotech to change the world and make handsome returns for investors. With the Delta variant wrecking devastation worldwide, join this presentation to discover what's next. Can an oral vaccine be the difference maker to finally tame Covid-19?

Newsletter Contributions

Medical Technology Stock Letter

The Medical Technology Stock Letter (“MTSL“) is published 24 times per year and offers unique perspectives on medical trends, portfolio companies and focus on diversification and risk management strategies to help investors profit from today’s market volatility.

Learn More